Nitric oxide and mitochondria in metabolic syndrome

Larisa Litvinova, Dmitriy N. Atochin, Nikolai Fattakhov, Mariia Vasilenko, Pavel Zatolokin, Elena Kirienkova

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Metabolic syndrome (MS) is a cluster of metabolic disorders that collectively increase the risk of cardiovascular disease. Nitric oxide (NO) plays a crucial role in the pathogeneses of MS components and is involved in different mitochondrial signaling pathways that control respiration and apoptosis. The present review summarizes the recent information regarding the interrelations of mitochondria and NO in MS. Changes in the activities of different NO synthase isoforms lead to the formation of metabolic disorders and therefore are highlighted here. Reduced endothelial NOS activity and NO bioavailability, as the main factors underlying the endothelial dysfunction that occurs in MS, are discussed in this review in relation to mitochondrial dysfunction. We also focus on potential therapeutic strategies involving NO signaling pathways that can be used to treat patients with metabolic disorders associated with mitochondrial dysfunction. The article may help researchers develop new approaches for the diagnosis, prevention and treatment of MS.

Original languageEnglish
Article number20
JournalFrontiers in Physiology
Volume6
Issue numberFEB
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Mitochondria
Nitric Oxide
Nitric Oxide Synthase
Biological Availability
Protein Isoforms
Respiration
Cardiovascular Diseases
Research Personnel
Apoptosis
Therapeutics

Keywords

  • Metabolic syndrome
  • Mitochondrial dysfunction
  • Mitochondrial nitric oxide synthase
  • Nitric oxide
  • Nitric oxide synthase
  • Nitric oxide synthase type I
  • Nitric oxide synthase type II
  • Oxide synthase type III

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Litvinova, L., Atochin, D. N., Fattakhov, N., Vasilenko, M., Zatolokin, P., & Kirienkova, E. (2015). Nitric oxide and mitochondria in metabolic syndrome. Frontiers in Physiology, 6(FEB), [20]. https://doi.org/10.3389/fphys.2015.00020

Nitric oxide and mitochondria in metabolic syndrome. / Litvinova, Larisa; Atochin, Dmitriy N.; Fattakhov, Nikolai; Vasilenko, Mariia; Zatolokin, Pavel; Kirienkova, Elena.

In: Frontiers in Physiology, Vol. 6, No. FEB, 20, 2015.

Research output: Contribution to journalReview article

Litvinova, L, Atochin, DN, Fattakhov, N, Vasilenko, M, Zatolokin, P & Kirienkova, E 2015, 'Nitric oxide and mitochondria in metabolic syndrome', Frontiers in Physiology, vol. 6, no. FEB, 20. https://doi.org/10.3389/fphys.2015.00020
Litvinova L, Atochin DN, Fattakhov N, Vasilenko M, Zatolokin P, Kirienkova E. Nitric oxide and mitochondria in metabolic syndrome. Frontiers in Physiology. 2015;6(FEB). 20. https://doi.org/10.3389/fphys.2015.00020
Litvinova, Larisa ; Atochin, Dmitriy N. ; Fattakhov, Nikolai ; Vasilenko, Mariia ; Zatolokin, Pavel ; Kirienkova, Elena. / Nitric oxide and mitochondria in metabolic syndrome. In: Frontiers in Physiology. 2015 ; Vol. 6, No. FEB.
@article{5b5ae49331d049898a1bc5cf0bf03290,
title = "Nitric oxide and mitochondria in metabolic syndrome",
abstract = "Metabolic syndrome (MS) is a cluster of metabolic disorders that collectively increase the risk of cardiovascular disease. Nitric oxide (NO) plays a crucial role in the pathogeneses of MS components and is involved in different mitochondrial signaling pathways that control respiration and apoptosis. The present review summarizes the recent information regarding the interrelations of mitochondria and NO in MS. Changes in the activities of different NO synthase isoforms lead to the formation of metabolic disorders and therefore are highlighted here. Reduced endothelial NOS activity and NO bioavailability, as the main factors underlying the endothelial dysfunction that occurs in MS, are discussed in this review in relation to mitochondrial dysfunction. We also focus on potential therapeutic strategies involving NO signaling pathways that can be used to treat patients with metabolic disorders associated with mitochondrial dysfunction. The article may help researchers develop new approaches for the diagnosis, prevention and treatment of MS.",
keywords = "Metabolic syndrome, Mitochondrial dysfunction, Mitochondrial nitric oxide synthase, Nitric oxide, Nitric oxide synthase, Nitric oxide synthase type I, Nitric oxide synthase type II, Oxide synthase type III",
author = "Larisa Litvinova and Atochin, {Dmitriy N.} and Nikolai Fattakhov and Mariia Vasilenko and Pavel Zatolokin and Elena Kirienkova",
year = "2015",
doi = "10.3389/fphys.2015.00020",
language = "English",
volume = "6",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",
number = "FEB",

}

TY - JOUR

T1 - Nitric oxide and mitochondria in metabolic syndrome

AU - Litvinova, Larisa

AU - Atochin, Dmitriy N.

AU - Fattakhov, Nikolai

AU - Vasilenko, Mariia

AU - Zatolokin, Pavel

AU - Kirienkova, Elena

PY - 2015

Y1 - 2015

N2 - Metabolic syndrome (MS) is a cluster of metabolic disorders that collectively increase the risk of cardiovascular disease. Nitric oxide (NO) plays a crucial role in the pathogeneses of MS components and is involved in different mitochondrial signaling pathways that control respiration and apoptosis. The present review summarizes the recent information regarding the interrelations of mitochondria and NO in MS. Changes in the activities of different NO synthase isoforms lead to the formation of metabolic disorders and therefore are highlighted here. Reduced endothelial NOS activity and NO bioavailability, as the main factors underlying the endothelial dysfunction that occurs in MS, are discussed in this review in relation to mitochondrial dysfunction. We also focus on potential therapeutic strategies involving NO signaling pathways that can be used to treat patients with metabolic disorders associated with mitochondrial dysfunction. The article may help researchers develop new approaches for the diagnosis, prevention and treatment of MS.

AB - Metabolic syndrome (MS) is a cluster of metabolic disorders that collectively increase the risk of cardiovascular disease. Nitric oxide (NO) plays a crucial role in the pathogeneses of MS components and is involved in different mitochondrial signaling pathways that control respiration and apoptosis. The present review summarizes the recent information regarding the interrelations of mitochondria and NO in MS. Changes in the activities of different NO synthase isoforms lead to the formation of metabolic disorders and therefore are highlighted here. Reduced endothelial NOS activity and NO bioavailability, as the main factors underlying the endothelial dysfunction that occurs in MS, are discussed in this review in relation to mitochondrial dysfunction. We also focus on potential therapeutic strategies involving NO signaling pathways that can be used to treat patients with metabolic disorders associated with mitochondrial dysfunction. The article may help researchers develop new approaches for the diagnosis, prevention and treatment of MS.

KW - Metabolic syndrome

KW - Mitochondrial dysfunction

KW - Mitochondrial nitric oxide synthase

KW - Nitric oxide

KW - Nitric oxide synthase

KW - Nitric oxide synthase type I

KW - Nitric oxide synthase type II

KW - Oxide synthase type III

UR - http://www.scopus.com/inward/record.url?scp=84926506969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926506969&partnerID=8YFLogxK

U2 - 10.3389/fphys.2015.00020

DO - 10.3389/fphys.2015.00020

M3 - Review article

VL - 6

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

IS - FEB

M1 - 20

ER -